Payment overview · 2025
General Payments
$291.67
12 reported records · 7 companies
Healthcare provider profile · identity verified
Elena Xintavelonis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LUMBERTON, TX · NPI 1750697280
Verified facts
What the public records show
CMS Open Payments records show Elena Xintavelonis, MD received $291.67 in general payments during 2025 across 12 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ozempic, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Ozempic by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.77 | 28.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $72.44 | 24.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.41 | 15.6% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $30.66 | 10.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $21.43 | 7.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.90 | 6.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.06 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $291.67 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $83.77 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $56.91 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.91 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.41 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $30.66 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 47 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 164 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
50 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
127 | 28 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
164 | 40 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 366 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 122 |
| Montelukast Sodium | Montelukast Sodium | 329 | 139 |
| Losartan Potassium | Losartan Potassium | 296 | 98 |
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 103 |
| Metformin Hcl | Metformin Hcl | 266 | 88 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 99 |
| Lisinopril | Lisinopril | 248 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 242 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 190 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 58 |
| Ozempic | Semaglutide | 164 | 40 |
| Furosemide | Furosemide | 163 | 67 |
| Alprazolam | Alprazolam | 145 | 38 |
| Carvedilol | Carvedilol | 143 | 44 |
| Omeprazole | Omeprazole | 136 | 51 |
| Sertraline Hcl | Sertraline Hcl | 130 | 45 |
| Farxiga | Dapagliflozin Propanediol | 127 | 28 |
| Azithromycin | Azithromycin | 117 | 86 |
| Fluticasone Propionate | Fluticasone Propionate | 117 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 35 |
| Simvastatin | Simvastatin | 109 | 41 |
| Spironolactone | Spironolactone | 109 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 34 |
| Fluconazole | Fluconazole | 105 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 34 |
| Tramadol Hcl | Tramadol Hcl | 102 | 30 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 97 | 23 |
| Trazodone Hcl | Trazodone Hcl | 94 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 39 |
| Progesterone | Progesterone, Micronized | 84 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 21 |
| Myrbetriq | Mirabegron | 80 | 23 |
| Eliquis | Apixaban | 77 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 29 |
| Potassium Chloride | Potassium Chloride | 76 | 32 |
| Zafirlukast | Zafirlukast | 75 | 28 |
| Allopurinol | Allopurinol | 73 | 29 |
| Mounjaro | Tirzepatide | 72 | suppressed |
| Nifedipine Er | Nifedipine | 72 | 22 |
| Clonazepam | Clonazepam | 69 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 66 | 19 |
| Prednisone | Prednisone | 62 | 38 |
| Buspirone Hcl | Buspirone Hcl | 61 | 20 |
| Pregabalin | Pregabalin | 60 | 23 |
| Jardiance | Empagliflozin | 58 | 15 |
| Meloxicam | Meloxicam | 56 | 28 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | 18 |
| Ibuprofen | Ibuprofen | 54 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 18 |
| Ezetimibe | Ezetimibe | 50 | 19 |
| Synthroid | Levothyroxine Sodium | 50 | 17 |
| Famotidine | Famotidine | 49 | 29 |
| Venlafaxine Hcl | Venlafaxine Hcl | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | 17 |
| Gemtesa | Vibegron | 47 | 13 |
| Methocarbamol | Methocarbamol | 47 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 17 |
| Methylprednisolone | Methylprednisolone | 44 | 40 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 30 |
| Anastrozole | Anastrozole | 40 | 14 |
| Donepezil Hcl | Donepezil Hcl | 39 | 12 |
| Vascepa | Icosapent Ethyl | 38 | suppressed |
| Xarelto | Rivaroxaban | 37 | 14 |
| Mirtazapine | Mirtazapine | 36 | 11 |
| Np Thyroid | Thyroid,pork | 36 | suppressed |
| Armour Thyroid | Thyroid,pork | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Lorazepam | Lorazepam | 35 | 12 |
| Valsartan | Valsartan | 35 | 12 |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 12 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | 11 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Finasteride | Finasteride | 29 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Nateglinide | Nateglinide | 28 | 13 |
| Telmisartan | Telmisartan | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 11 |
| Temazepam | Temazepam | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | 13 |
| Nitroglycerin | Nitroglycerin | 23 | 14 |
| Baclofen | Baclofen | 22 | 11 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Metronidazole | Metronidazole | 19 | 18 |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 11 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 17 |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Risperidone | Risperidone | 17 | suppressed |
| Ubrelvy | Ubrogepant | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Estradiol | Estradiol | 15 | 11 |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | 11 |
| Naproxen | Naproxen | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Protonix | Pantoprazole Sodium | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $291.67 · 12 records | AstraZeneca Pharmaceuticals LP | BREZTRI, DUPIXENT, GEMTESA, Kerendia, Korlym, Ozempic, QULIPTA, Rybelsus, UBRELVY, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error